EA202190036A1 - Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение - Google Patents

Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение

Info

Publication number
EA202190036A1
EA202190036A1 EA202190036A EA202190036A EA202190036A1 EA 202190036 A1 EA202190036 A1 EA 202190036A1 EA 202190036 A EA202190036 A EA 202190036A EA 202190036 A EA202190036 A EA 202190036A EA 202190036 A1 EA202190036 A1 EA 202190036A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline form
compound
diseases
activity
application
Prior art date
Application number
EA202190036A
Other languages
English (en)
Russian (ru)
Inventor
Ицянь Ван
Чуньхуэй Чжан
Цзябин ВАН
Лемин ДИН
Original Assignee
Бетта Фармасьютикалз Ко., Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бетта Фармасьютикалз Ко., Лтд filed Critical Бетта Фармасьютикалз Ко., Лтд
Publication of EA202190036A1 publication Critical patent/EA202190036A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA202190036A 2018-06-21 2019-06-21 Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение EA202190036A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018092194 2018-06-21
PCT/CN2019/092239 WO2019242719A1 (fr) 2018-06-21 2019-06-21 Forme cristalline d'un composé inhibiteur de l'activité cdk4/6 et son utilisation

Publications (1)

Publication Number Publication Date
EA202190036A1 true EA202190036A1 (ru) 2021-03-24

Family

ID=68983152

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190036A EA202190036A1 (ru) 2018-06-21 2019-06-21 Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение

Country Status (15)

Country Link
US (1) US12043622B2 (fr)
EP (1) EP3812386A4 (fr)
JP (1) JP7430656B2 (fr)
KR (1) KR20210024004A (fr)
CN (2) CN112424202B (fr)
AU (1) AU2019290722B2 (fr)
BR (1) BR112020026052A2 (fr)
CA (1) CA3104365A1 (fr)
EA (1) EA202190036A1 (fr)
IL (1) IL279579B2 (fr)
MX (1) MX2020013847A (fr)
PH (1) PH12020552236A1 (fr)
SG (1) SG11202012858QA (fr)
TW (1) TWI786303B (fr)
WO (1) WO2019242719A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202300145A (zh) * 2021-03-24 2023-01-01 大陸商貝達藥業股份有限公司 藥物組合、包含其的試劑盒及其用途
WO2023131179A1 (fr) * 2022-01-05 2023-07-13 贝达药业股份有限公司 Utilisation d'un dérivé de benzimidazole ou d'un sel de celui-ci dans le traitement de la leucémie
CN115872923B (zh) * 2022-12-29 2023-04-28 成都泰和伟业生物科技有限公司 一种化合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016015605A1 (fr) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Composés en tant que petites molécules inhibitrices de la cdk et leurs utilisations
CN104592251B (zh) * 2015-01-23 2019-10-01 上海复星医药产业发展有限公司 4-(稠杂环取代氨基)-1h-吡唑-3-甲酰胺类化合物及其用途
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
JP2018519353A (ja) * 2015-07-08 2018-07-19 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft RORcモジュレーターとしてのアリールスルタム誘導体
CN106608879A (zh) * 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
WO2017102796A1 (fr) * 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag Dérivés d'hétéroarylamide sultame en tant que modulateurs de rorc
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
KR102543603B1 (ko) * 2016-12-22 2023-06-14 베타 파머수티컬 컴퍼니 리미티드 벤조이미다졸 유도체, 제조 방법 및 그것의 용도
US11351170B2 (en) * 2017-08-15 2022-06-07 Beijing Xuanyi Pharmasciences Co., Ltd. Substituted pyrimidines as CDK4/6 inhibitors

Also Published As

Publication number Publication date
US12043622B2 (en) 2024-07-23
JP2021529175A (ja) 2021-10-28
AU2019290722B2 (en) 2023-12-21
JP7430656B2 (ja) 2024-02-13
EP3812386A1 (fr) 2021-04-28
SG11202012858QA (en) 2021-02-25
CN112424202A (zh) 2021-02-26
MX2020013847A (es) 2021-04-28
WO2019242719A1 (fr) 2019-12-26
IL279579A (en) 2021-03-01
TWI786303B (zh) 2022-12-11
CN113861191B (zh) 2023-09-19
CN112424202B (zh) 2021-09-17
KR20210024004A (ko) 2021-03-04
AU2019290722A1 (en) 2021-01-28
IL279579B2 (en) 2023-02-01
IL279579B (en) 2022-10-01
TW202016114A (zh) 2020-05-01
CN113861191A (zh) 2021-12-31
PH12020552236A1 (en) 2021-06-28
US20210261546A1 (en) 2021-08-26
BR112020026052A2 (pt) 2021-03-23
EP3812386A4 (fr) 2022-03-30
CA3104365A1 (fr) 2019-12-26

Similar Documents

Publication Publication Date Title
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
NZ590784A (en) Pyrazolopyridine kinase inhibitors
HRP20180483T1 (hr) Spoj kinolona
HRP20201094T1 (hr) IMIDAZO[1,2-a]PIRIDINI, NAMIJENJENI LIJEČENJU ILI SPRJEČAVANJU HIPERURIKEMIJE ILI GIHTA
WO2017205536A3 (fr) Composés thérapeutiques et leurs utilisations
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
CA2548654A1 (fr) Derives piperidine-amino-benzimidazole en tant qu'inhibiteurs de la replication du virus respiratoire syncytial
EA201300620A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
PH12020552236A1 (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
NZ588830A (en) Inhibitors of protein kinases
EA201492112A1 (ru) ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
JP2016540803A5 (fr)
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
BRPI0408605A (pt) derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos
PE20142244A1 (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina
PH12020500583A1 (en) 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases
MX339302B (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
EA201691934A1 (ru) Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1
WO2016010869A3 (fr) Composés de quinoléine fusionnés utilisés comme inhibiteurs de la voie de signalisation pi3k/mtor
MY195177A (en) Pyrazole Derivative or Pharmaceutically Acceptable Salt Thereof